Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > BUSINESS
BUSINESS
- Teva Takeda to Copromote Allermist AG with Ceolia
March 28, 2023
- Japanese Man Detained in China was Astellas Employee
March 27, 2023
- Novartis Japan Sees 2023 OK for 1st siRNA Drug for Hyperlipidemia, 7 Approvals to Drive Growth
March 27, 2023
- Takeda Puts Up 100 Billion Yen for New Plasma Therapy Facility in Japan
March 24, 2023
- Ono, Kasawaki-Based AI Platform Firm Tie Up on Antibody Drug Discovery
March 24, 2023
- Hutchmed’s Colorectal Cancer Med Logs Positive Data in Japanese Cohort: Takeda
March 24, 2023
- Ono, Macomics Ink Macrophage Drug Discovery Deal
March 24, 2023
- Opdivo Gets South Korea OK for 1st Line Esophageal Cancer
March 24, 2023
- Detailed Data Out for PIII Zolbetuximab Study in 1st-Line Gastric Cancer: Astellas
March 23, 2023
- Kowa Launches Global PIII for Ripasudil for Fuchs Endothelial Corneal Dystrophy
March 23, 2023
- Senju Starts Japan PIII for Dry Eye Med; Takeda to Be Distributor If Approved
March 23, 2023
- Kobayashi Kako to Withdraw Marketing License on April 1
March 23, 2023
- Pfizer Japan Starts Commercial Rollout of COVID-19 Pill Paxlovid
March 23, 2023
- Opdivo-Yervoy Combo Approved for HCC in Taiwan
March 23, 2023
- Eisai Publishes Updated Social Value Simulation for Lecanemab
March 22, 2023
- Daiichi Sankyo Rolls Out Lung, Breast Cancer Data for HER3-Directed ADC
March 22, 2023
- Mitsubishi Tanabe Files Canaglu OD Tablet Form in Japan
March 22, 2023
- Xtandi Plus Leuprolide Meet PIII Goal in Non-Metastatic Prostate Cancer: Astellas
March 20, 2023
- Takeda Updates Qdenga Peak Sales Estimate to US$1.6-2 Billion
March 17, 2023
- Fujifilm to Make Foray into Drug Discovery CRO Business
March 17, 2023
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…